Home › COPD › Minnesota › Rochester
COPD clinical trials in Rochester, MN
3 studies for COPD are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RecruitingPhase 3
- Mayo Clinic in Rochester - Minnesota- Site Number : 8400005, Rochester
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
RecruitingPhase 3
- GC2501 Study Site 108, Rochester
Pulmonary Rehabilitation for Rural Patients With COPD
Recruiting
- Mayo Clinic in Rochester, Rochester
About COPD
COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. At first symptoms are mild, but they usually become more severe. Learn more.
More about COPD on MedlinePlus
COPD trials in other cities
- Philadelphia, PA23 studies
- Miami, FL18 studies
- Birmingham, AL17 studies
- Boston, MA17 studies
- Orlando, FL15 studies
- Houston, TX15 studies
- Baltimore, MD14 studies
- Chicago, IL14 studies
- Dallas, TX12 studies
- Pittsburgh, PA12 studies
- New York City, NY11 studies
- Ann Arbor, MI10 studies
Other studies in Rochester
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer37 studies
- Metastatic Cancer31 studies
- Cancer (all types)30 studies
- Colorectal Cancer29 studies
- Ovarian Cancer29 studies
- Multiple Myeloma24 studies
- Prostate Cancer22 studies
- Heart Failure22 studies
- Pancreatic Cancer22 studies
- Lung Cancer20 studies
- Endometrial Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.